期刊文献+

三种酰腙类Schiff碱的锌配合物的合成、晶体结构与表征 被引量:2

Syntheses, Crystal Structures, and Characterization of Three Zinc Complexs with Different Acylhydrazone-Type Schiff Base Ligands
下载PDF
导出
摘要 采用不同的方法合成了3种酰腙的锌配合物[Zn(Lss)(phen)(DMF)](1)、{[Zn(HLdis)]2·2CH3OH}n(2)和[Zn(Baf)2]·CH3OH(3),通过元素分析、红外光谱、紫外光谱和热重分析进行了表征,并经X射线单晶衍射分析它们晶体结构。1和3的晶体属于三斜晶系P1空间群,Zn(Ⅱ)的配位数为6;2属于单斜晶系P21/n空间群,Zn(Ⅱ)的配位数为5。3的前驱体是一种吡唑啉类化合物(C15H14N2O3,Pzl),它的晶体属于单斜晶系P21/c空间群;Pzl与锌离子配位时发生分子重排,开环产物HBaf以酰腙结构与Zn(Ⅱ)配位形成3。 Three zinc complexes,namely[Zn(Lss)(phen)(DMF)](1),{[Zn(HLdis)]2·2CH3OH}n(2)and[Zn(Baf)2]·CH3OH(3),formed from different acylhydrazone-type Schiff base ligands were synthesized by using different methods,and the compounds were characterized by IR,UV-Vis spectra and TGA.The X-ray diffraction analyses reveal that 1 and 3 crystallize in the triclinic space group P1 while 2 in monoclinic system space group P21/n.In 1 and 3,coordination number of the Zn(Ⅱ)is six,and the centric atom locate in a distorted octahedron geometry,while in 2 Zn(Ⅱ)is five-coordination in a distorted square-pyramidal geometry.The precursor of 3 is pyrazoline derivative with the formula C15H14N2O3(Pzl)crystallizing in monoclinic system space group P21/c.Due to the coordination of Zn(Ⅱ)causing the intramolecular rearrangement of Pzl,the ring open product HBaf in the form of an acylhydrazone structure coordinates with Zn(Ⅱ)to form complex 3.CCDC:1465235,1;1404501,2;1516696,3;1516192,Pzl.
作者 解庆范 陈延民 XIE Qing-Fan;CHEN Yan-Min(College of Chemical Engineering and Material,Quanzhou Normal University,Quanzhou,Fujian 362000,China)
出处 《无机化学学报》 SCIE CAS CSCD 北大核心 2019年第12期2209-2216,共8页 Chinese Journal of Inorganic Chemistry
关键词 SCHIFF碱 锌配合物 晶体结构 光谱性质 Schiff base zinc complex crystal structure spectral properties
  • 相关文献

参考文献2

二级参考文献22

  • 1XIE Qing-Fan(解庆范), GAO Ping-Zhang(高平章), CHEN Yan-Min(陈延民).无机化学学报, 2014, 30(10):2382-2388.
  • 2Rosenberg B, Van Camp L, Trosko J E, et al. Nature, 1969, 222:385-386.
  • 3Jungwirth U, Kowol C R, Keppler B K, et al. Antioxid. Redox Signaling, 2011,15(4): 1085-1127.
  • 4Garbutcheon-singh K B, Grant M P, Harper B P, et al. Curr. Top. Med. Chem., 2011,11:521-542.
  • 5Duraisamy S R, Nattamai S P. Eur. J. Med. Chem., 2011,46 (45):4584-4594.
  • 6Li X W, Yan C W. lnorg. Chim. Aeta, 2011,367(1):64-72.
  • 7Ramakrishnan S, Shakthipriya D, Suresh E, et al. Inorg. Chem., 2011,50:6458-6471.
  • 8Prabbakaran P, Kalaivani P. J. Inorg. Bioehem., 2013,18(2): 233-247.
  • 9Eswaran R, Karuppannan N. RSC Adv., 2012,2(46):8515- 8525.
  • 10Krishnamoorthy P, Dharmaraj N. RSC Adv., 2012,2 (56): 12190-12203.

共引文献11

同被引文献9

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部